Discovery of novel microsomal prostaglandin E2 synthase 1 (mPGES-1) inhibitors by a structurally inspired virtual screening study

被引:0
|
作者
Olgac, Abdurrahman [1 ,2 ]
Jordan, Paul M. [3 ]
Kretzer, Christian [3 ]
Werz, Oliver [3 ]
Banoglu, Erden [1 ]
机构
[1] Gazi Univ, Fac Pharm, Dept Pharmaceut Chem, TR-06560 Ankara, Turkiye
[2] Evias Pharmaceut R&D Ltd, Dept Drug Discovery, Gazi Teknopk, TR-06830 Ankara, Turkiye
[3] Friedrich Schiller Univ Jena, Dept Pharmaceut Med Chem, D-07743 Jena, Germany
来源
JOURNAL OF MOLECULAR GRAPHICS & MODELLING | 2025年 / 136卷
关键词
Prostaglandin; mPGES-1; Cyclooxygenase; Arachidonic acid; Docking; Virtual screening; E-2; SYNTHASE-1; ACCURATE DOCKING; IDENTIFICATION; POTENT; INTERFERENCE; PROTEINS; DESIGN; GLIDE;
D O I
10.1016/j.jmgm.2025.108962
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Prostaglandin (PG) E2 is a pro-inflammatory lipid mediator derived from the metabolism of arachidonic acid (AA) by cyclooxygenases (COX) and PGE2 synthases. Nonsteroidal anti-inflammatory drugs (NSAIDs), commonly used in the treatment of inflammation, nonselectively inhibit COX activity and decrease PGE2 production. However, these drugs cause gastrointestinal bleeding and several cardiovascular complications. Therefore, inhibiting microsomal PGE2 Synthase-1 (mPGES-1) to block PGE2 production downstream of COX is expected to yield safer and more effective treatments for inflammation, cancer, and cardiovascular diseases. At present, there are no mPGES-1 inhibitors available on the market, but ongoing research continuously evaluates new compounds in both preclinical and clinical stages. Here, we conducted a high throughput virtual screening campaign to discover novel mPGES-1 inhibitor scaffolds. This campaign utilized physicochemical filtering alongside both structure-aware ligand-based approaches (shape screening templates and pharmacophore models, which were generated based on the 3D binding modes of the co-crystallized mPGES-1 inhibitors) and structure-based strategies (refinement with docking and molecular dynamics). Thirty-four compounds were selected and biologically tested for mPGES-1 inhibition in a cell-free assay using microsomes from interleukin-1 beta-stimulated A549 cells as the source of mPGES-1. The most potent compound inhibited the remaining enzyme activity with an IC50 value of 6.46 mu M in a cell-free assay for PGE2 production. We also compared the binding patterns of the most active compounds identified in this study with those of co-crystallized inhibitors using molecular dynamics simulations. This comparison underscored the crucial role of ionic interactions, it-it interactions, hydrogen bonds, and water bridges involving specific amino acids. Our results highlight the importance of these interaction networks within the binding cavity in various binding scenarios. Ultimately, the insights gained from this study could assist in designing and developing new mPGES-1 inhibitors.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] A Multi-step Virtual Screening Protocol for the Identification of Novel Non-acidic Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors
    Shekfeh, Suhaib
    Caliskan, Burcu
    Fischer, Katrin
    Yalcin, Tansu
    Garscha, Ulrike
    Werz, Oliver
    Banoglu, Erden
    CHEMMEDCHEM, 2019, 14 (02) : 273 - 281
  • [2] Novel 1,3,4-oxadiazole derivatives as highly potent microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors
    Maz, Tugce Gur
    Dahlke, Philipp
    Ergul, Azize Gizem
    Olgac, Abdurrahman
    Jordan, Paul M.
    Caliskan, Burcu
    Werz, Oliver
    Banoglu, Erden
    BIOORGANIC CHEMISTRY, 2024, 147
  • [3] Identification of novel microsomal prostaglandin E2 synthase-1 (mPGES-1) lead inhibitors from Fragment Virtual Screening
    Lauro, Gianluigi
    Manfra, Michele
    Pedatella, Silvana
    Fischer, Katrin
    Cantone, Vincenza
    Terracciano, Stefania
    Bertamino, Alessia
    Ostacolo, Carmine
    Gomez-Monterrey, Isabel
    De Nisco, Mauro
    Riccio, Raffaele
    Novellino, Ettore
    Werz, Oliver
    Campiglia, Pietro
    Bifulco, Giuseppe
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 125 : 278 - 287
  • [4] HQSAR study of microsomal prostaglandin E2 synthase (mPGES-1) inhibitors
    San Juan, Amor A.
    Cho, Seung Joo
    Cho, Hoon
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2006, 27 (10) : 1531 - 1536
  • [5] Discovery of N-amido-phenylsulfonamide derivatives as novel microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors
    Kim, Misong
    Kim, Geuntae
    Kang, Minji
    Ko, Dohyeong
    Nam, Yunchan
    Moon, Chang Sang
    Kang, Heung Mo
    Shin, Ji-Sun
    Werz, Oliver
    Lee, Kyung-Tae
    Lee, Jae Yeol
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 41
  • [6] Virtual screening, molecular simulations and bioassays: Discovering novel microsomal prostaglandin E Synthase-1 (mPGES-1) inhibitors
    Babaoglu, Zeynep Yagmur
    Kilic, Deryanur
    COMPUTERS IN BIOLOGY AND MEDICINE, 2023, 155
  • [7] 3D-QSAR study of microsomal prostaglandin E2 synthase(mPGES-1) inhibitors
    Amor A. San Juan
    Seung Joo Cho
    Journal of Molecular Modeling, 2007, 13 : 601 - 610
  • [8] 3D-QSAR study of microsomal prostaglandin E2 synthase (mPGES-1) inhibitors
    San Juan, Amor A.
    Cho, Seung Joo
    JOURNAL OF MOLECULAR MODELING, 2007, 13 (05) : 601 - 610
  • [9] Insights on Microsomal Prostaglandin E2 Synthase 1 (mPGES-1) Inhibitors using Molecular Dynamics and MM/PBSA Calculations
    dos Santos Nascimento, Igor Jose
    de Aquino, Thiago Mendonca
    da Silva Junior, Edeildo Ferreira
    de Moura, Ricardo Olimpio
    LETTERS IN DRUG DESIGN & DISCOVERY, 2024, 21 (06) : 1033 - 1047
  • [10] Arylpyrrolizines as Inhibitors of Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) or as Dual Inhibitors of mPGES-1 and 5-Lipoxygenase (5-LOX)
    Liedtke, Andy J.
    Keck, Peter R. W. E. F.
    Lehmann, Frank
    Koeberle, Andreas
    Werz, Oliver
    Laufer, Stefan A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (15) : 4968 - 4972